Skip to main content

Using a Modified Yeast Two-Hybrid System to Screen for Chemical GEF Inhibitors

  • Protocol
  • First Online:
Rational Drug Design

Part of the book series: Methods in Molecular Biology ((MIMB,volume 928))

Abstract

GTPases of the Ras superfamily act as signaling switches, active when bound to GTP and inactive when bound to GDP. There is now considerable evidence that over-activation of Ras-like pathways participates in the development of many cancer types. In particular, GTPases of the Rho family control cell adhesion, survival, motility, and invasion, cell properties dysregulated in most cancer types. Rho activation is triggered by RhoGEFs, most of which form complexes with growth-factor receptors and initiate downstream Rho signaling pathways in response to extracellular clues. As such, RhoGEFs represent attractive targets to inhibit Rho pathways and may have interesting druggability for cancer therapeutics. Here we describe a procedure derived from the yeast two-hybrid system, in which activation of a mammalian Rho GTPase by its cognate RhoGEF is converted into variation in the yeast growth. The experimental design is thus suitable for identiying RhoGEF inhibitors and has been optimized for medium-throughput screening. The major advantages of this method lie in the direct monitoring of GEF activity in a living organism and the rapid detection of false positive hits.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Shirai H, Autieri M, Eguchi S (2007) Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Curr Opin Nephrol Hypertens 16:111–5

    Article  PubMed  CAS  Google Scholar 

  2. Fritz G, Just I, Kaina B (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81:682–7

    Article  PubMed  CAS  Google Scholar 

  3. Bosco EE, Mulloy JC, Zheng Y (2009) Rac1 GTPase: a “Rac” of all trades. Cell Mol Life Sci 66:370–4

    Article  PubMed  CAS  Google Scholar 

  4. Boureux A, Vignal E, Faure S, Fort P (2007) Evolution of the Rho family of ras-like GTPases in eukaryotes. Mol Biol Evol 24:203–16

    Article  PubMed  CAS  Google Scholar 

  5. Rossman KL, Der CJ, Sondek J (2005) GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 6:167–80

    Article  PubMed  CAS  Google Scholar 

  6. Meller N, Merlot S, Guda C (2005) CZH proteins: a new family of Rho-GEFs. J Cell Sci 118:4937–46

    Article  PubMed  CAS  Google Scholar 

  7. Diaz-Flores E, Shannon K (2007) Targeting oncogenic Ras. Genes Dev 21:1989–92

    Article  PubMed  CAS  Google Scholar 

  8. Vega FM, Ridley AJ (2008) Rho GTPases in cancer cell biology. FEBS Lett 582:2093–101

    Article  PubMed  CAS  Google Scholar 

  9. Lazer G, Katzav S (2010) Guanine nucleotide exchange factors for RhoGTPases: Good therapeutic targets for cancer therapy? Cell Signal 23:969–79

    Article  PubMed  Google Scholar 

  10. Leonard DA, Evans T, Hart M, Cerione RA, Manor D (1994) Investigation of the GTP-binding/GTPase cycle of Cdc42Hs using fluorescence spectroscopy. Biochemistry 33:12323–8

    Article  PubMed  CAS  Google Scholar 

  11. Sander EE, van Delft S, ten Klooster JP, Reid T, van der Kammen RA, Michiels F, Collard JG (1998) Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. J Cell Biol 143:1385–98

    Article  PubMed  CAS  Google Scholar 

  12. Zheng Y, Hart MJ, Cerione RA (1995) Guanine nucleotide exchange catalyzed by dbl oncogene product. Methods Enzymol 256:77–84

    Article  PubMed  CAS  Google Scholar 

  13. De Toledo M, Colombo K, Nagase T, Ohara O, Fort P, Blangy A (2000) The yeast exchange assay, a new complementary method to screen for Dbl-like protein specificity: identification of a novel RhoA exchange factor. FEBS Lett 480:287–92

    Article  PubMed  Google Scholar 

  14. Blangy A, Bouquier N, Gauthier-Rouviere C, Schmidt S, Debant A, Leonetti JP, Fort P (2006) Identification of TRIO-GEFD1 chemical inhibitors using the yeast exchange assay. Biol Cell 98:511–22

    Article  PubMed  CAS  Google Scholar 

  15. Bouquier N, Vignal E, Charrasse S, Weill M, Schmidt S, Leonetti JP, Blangy A, Fort P (2009) A cell active chemical GEF inhibitor selectively targets the Trio/RhoG/Rac1 signaling pathway. Chem Biol 16:657–66

    Article  PubMed  CAS  Google Scholar 

  16. Vives V, Laurin M, Cres G, Larrousse P, Morichaud Z, Noel D, Cote JF, Blangy A (2011) The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts. J Bone Miner Res 26(5):1099–110

    Article  PubMed  CAS  Google Scholar 

  17. Vignal E, Blangy A, Martin M, Gauthier-Rouviere C, Fort P (2001) Kinectin is a key effector of RhoG microtubule-dependent cellular activity. Mol Cell Biol 21:8022–34

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are indebted to Pauline Larrousse for technical support. This work was funded by institutional grants from CNRS and Montpellier universities, and by contracts from ANR (ANR-06-PCVI-0024), ARC (n° 1048), FRM (DVO20081013473), and Arthritis Fondation Courtin (OPT30713).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Philippe Fort .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this protocol

Cite this protocol

Blangy, A., Fort, P. (2012). Using a Modified Yeast Two-Hybrid System to Screen for Chemical GEF Inhibitors. In: Zheng, Y. (eds) Rational Drug Design. Methods in Molecular Biology, vol 928. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-008-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-008-3_7

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-007-6

  • Online ISBN: 978-1-62703-008-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics